Strados Labs, a Philadelphia, PA-based medical technology company leveraging smart sensors, machine learning, and proprietary algorithms to provide early detection and predictions of worsening respiratory diseases, raised $4.5 million in pre-series A funding.
Backers included SOSV, cultivate (MD), Wavemaker360 Health, Blu Venture Investors, and Broad Street Angels.
The new funding comes on the heels of major commercial milestones including FDA Class II 510(k) clearance and CE Mark for its flagship product, RESPä, key contracts with major pharmaceutical partners for use in decentralized trials, the submission of four significant abstracts to the American Thoracic Society, and the appointment of Steve Bishop, former P&G Healthcare CEO, to the Strados Labs Board of Directors.
Company: Strados Labs Inc.
Round: pre-series A
Funding Month: January 2022
Additional Investors: SOSV, cultivate (MD), Wavemaker360 Health, Blu Venture Investors, and Broad Street Angels
Company Website: https://stradoslabs.com/
Software Category: smart sensor platforms
About the Company: Strados Labs is a medical technology company developing smart sensor platforms that utilize machine learning and proprietary algorithms to detect and predict compounding conditions associated with serious chronic respiratory diseases to improve the lives of patients globally. The Company developed a first-of-its-kind smart sensor platform for respiratory health, RESP™. Strados was recently granted a CE Mark for RESP™ and received its FDA Class II 510(k) clearance for it last December. The Company is developing a robust pipeline of other smart sensor platforms to support and address other chronic diseases, as well as chronic disease management. Strados will continue to target asthma, COPD, and infectious respiratory diseases (COVID, RSV, etc.) as it moves into 2022—with plans to add heart failure in late 2022. The Company is based in Philadelphia and is a privately held company.